Fact CheckerSign in

NCT05989802Recruiting

Rapid Research in Diagnostics Development for TB Network (R2D2 Kids) and Assessing Diagnostics At POC for TB in Children (ADAPT for Kids)

Rapid Research in Diagnostics Development for Tuberculosis Network (R2D2 Kids) and Assessing Diagnostics At Point-of-care for Tuberculosis in Children (ADAPT for Kids)

Source: ClinicalTrials.gov · Last updated 15 Oct 2026

Brief summary (registry, in English)

Every year there are an estimated 230,000 childhood deaths from TB. There is an urgent need for novel tests for TB diagnosis in children under 15 years. The Rapid Research in Diagnostics Development for TB Network (R2D2 Kids) and the Assessing Diagnostics at Point-of-care for Tuberculosis in children (ADAPT for Kids) studies seek to reduce the burden of TB worldwide by evaluating faster, simpler, and less expensive TB triage and diagnostic tests for use in children.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
2100 (estimated)
First submitted
28 Jul 2023
Start date
26 Jan 2024
Primary completion date
1 Sept 2030
Lead sponsor
University of California, San Francisco
Diseases
Tuberculosis
NCT number
NCT05989802

What you commit to

  • Study type: Interventional
  • Planned participants: 2100
  • From 26 Jan 2024 to the primary completion date, 1 Sept 2030
  • 3 sites in 3 countries
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Criteria the registry did not label

  • Participant eligibility criteria:
  • Participants will include children (age \<15 years) who present to care with:
  • 2 or more of the following:
  • Unexplained cough for any duration
  • TB contact or tuberculin skin test or interferon gamma release assay positive
  • Abnormal chest X-ray (any abnormality) OR
  • Any one of criteria A AND any one of the following:
  • Unexplained weight loss OR unexplained failure to thrive OR Severe Acute Malnutrition
  • Unexplained fever ≥2 weeks
  • Unexplained lethargy or reduced playfulness ≥2 weeks
    • The study will exclude participants who:
  • Completed preventive or active TB treatment within the past 12 months (to increase TB prevalence and reduce false-positive results, respectively);
  • Have taken any medication with anti-mycobacterial activity for any reason for greater than 3 days at the time of enrollment (to reduce false-negatives);
  • Are unable to return for follow-up visits; or
  • Whose parents/guardians are unwilling to provide informed consent or who are unwilling to provide assent if applicable (age determined by local IRB)
    • Assessment of the usability of novel TB tests:
    • The study will also include health workers at each clinical site who are 1) aged ≥18 years and 2) involved in routine TB testing (collecting specimens for or performing TB tests). Personnel who are unwilling to provide informed consent will be excluded.

Age in the registry: - to 65 years · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (3)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Instituto Nacional de Saude
Coordinator of this site? Confirm its status
MaputoMozambiqueRecruiting
Mulago National Referral Hospital
Coordinator of this site? Confirm its status
KampalaUgandaNot yet recruiting
Dora Nginza Hospital
Coordinator of this site? Confirm its status
Cape TownSouth AfricaNot yet recruiting

This page is information, not medical advice. Discuss any trial with your doctor.